Developed by : Institute of Nuclear Medicine and Allied Sciences (INMAS)
The Drugs Controller General of India (DCGI) has granted permission for emergency use of an anti-COVID-19 therapeutic application of the drug 2-deoxy-D-glucose (2-DG), developed by the Institute of Nuclear Medicine and Allied Sciences (INMAS), a lab of the Defence Research and Development Organisation (DRDO), in collaboration with Dr. Reddy’s Laboratories, Hyderabad. The drug comes in powder form in sachets and is taken orally by dissolving it in water. It accumulates in the virus infected cells and prevents their growth by stopping viral synthesis and energy production.
Sources : PIB